Literature DB >> 14973079

Acquisition of high-level chromosomal instability is associated with integration of human papillomavirus type 16 in cervical keratinocytes.

Mark R Pett1, William O F Alazawi, Ian Roberts, Sally Dowen, David I Smith, Margaret A Stanley, Nicholas Coleman.   

Abstract

Whereas two key steps in cervical carcinogenesis are integration of high-risk human papillomavirus (HR-HPV) and acquisition of an unstable host genome, the temporal association between these events is poorly understood. Chromosomal instability is induced when HR-HPV E7 oncoprotein is overexpressed from heterologous promoters in vitro. However, it is not known whether such events occur at the "physiologically" elevated levels of E7 produced by deregulation of the homologous HR-HPV promoter after integration. Indeed, an alternative possibility is that integration in vivo is favored in an already unstable host genome. We have addressed these issues using the unique human papillomavirus (HPV) 16-containing cervical keratinocyte cell line W12, which was derived from a low-grade squamous intraepithelial lesion and thus acquired HPV16 by "natural" infection. Whereas W12 at low passage contains HPV16 episomes only, long-term culture results in the emergence of cells containing integrated HPV16 only. We show that integration of HPV16 in W12 is associated with 3' deletion of the E2 transcriptional repressor, resulting in deregulation of the homologous promoter of the integrant and an increase in E7 protein levels. We further demonstrate that high-level chromosomal instability develops in W12 only after integration and that the forms of instability observed correlate with the physical state of HPV16 DNA and the level of E7 protein. Whereas intermediate E7 levels are associated with numerical chromosomal abnormalities, maximal levels are associated with both numerical and structural aberrations. HR-HPV integration is likely to be a critical event in cervical carcinogenesis, preceding the development of chromosomal abnormalities that drive malignant progression.

Entities:  

Mesh:

Year:  2004        PMID: 14973079     DOI: 10.1158/0008-5472.can-03-3214

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  68 in total

Review 1.  Mechanisms of human papillomavirus-induced oncogenesis.

Authors:  Karl Münger; Amy Baldwin; Kirsten M Edwards; Hiroyuki Hayakawa; Christine L Nguyen; Michael Owens; Miranda Grace; Kyungwon Huh
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

2.  The nature of telomere fusion and a definition of the critical telomere length in human cells.

Authors:  Rebecca Capper; Bethan Britt-Compton; Maira Tankimanova; Jan Rowson; Boitelo Letsolo; Stephen Man; Michele Haughton; Duncan M Baird
Journal:  Genes Dev       Date:  2007-10-01       Impact factor: 11.361

3.  HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress.

Authors:  Vonetta M Williams; Maria Filippova; Ubaldo Soto; Penelope J Duerksen-Hughes
Journal:  Future Virol       Date:  2011-01-01       Impact factor: 1.831

Review 4.  Viruses and human cancers: a long road of discovery of molecular paradigms.

Authors:  Martyn K White; Joseph S Pagano; Kamel Khalili
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

5.  In vitro progression of human papillomavirus 16 episome-associated cervical neoplasia displays fundamental similarities to integrant-associated carcinogenesis.

Authors:  Elizabeth Gray; Mark R Pett; Dawn Ward; David M Winder; Margaret A Stanley; Ian Roberts; Cinzia G Scarpini; Nicholas Coleman
Journal:  Cancer Res       Date:  2010-05-04       Impact factor: 12.701

Review 6.  Role of human papillomavirus in cutaneous squamous cell carcinoma: a meta-analysis.

Authors:  Jennifer Wang; Bishr Aldabagh; Justin Yu; Sarah Tuttleton Arron
Journal:  J Am Acad Dermatol       Date:  2014-04       Impact factor: 11.527

7.  Characterization of HPV and host genome interactions in primary head and neck cancers.

Authors:  Michael Parfenov; Chandra Sekhar Pedamallu; Nils Gehlenborg; Samuel S Freeman; Ludmila Danilova; Christopher A Bristow; Semin Lee; Angela G Hadjipanayis; Elena V Ivanova; Matthew D Wilkerson; Alexei Protopopov; Lixing Yang; Sahil Seth; Xingzhi Song; Jiabin Tang; Xiaojia Ren; Jianhua Zhang; Angeliki Pantazi; Netty Santoso; Andrew W Xu; Harshad Mahadeshwar; David A Wheeler; Robert I Haddad; Joonil Jung; Akinyemi I Ojesina; Natalia Issaeva; Wendell G Yarbrough; D Neil Hayes; Jennifer R Grandis; Adel K El-Naggar; Matthew Meyerson; Peter J Park; Lynda Chin; J G Seidman; Peter S Hammerman; Raju Kucherlapati
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-13       Impact factor: 11.205

8.  Dynamic localization of the human papillomavirus type 11 origin binding protein E2 through mitosis while in association with the spindle apparatus.

Authors:  Luan D Dao; Aaron Duffy; Brian A Van Tine; Shwu-Yuan Wu; Cheng-Ming Chiang; Thomas R Broker; Louise T Chow
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

9.  Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

Authors:  Cornelia L Trimble; Matthew P Morrow; Kimberly A Kraynyak; Xuefei Shen; Michael Dallas; Jian Yan; Lance Edwards; R Lamar Parker; Lynette Denny; Mary Giffear; Ami Shah Brown; Kathleen Marcozzi-Pierce; Divya Shah; Anna M Slager; Albert J Sylvester; Amir Khan; Kate E Broderick; Robert J Juba; Timothy A Herring; Jean Boyer; Jessica Lee; Niranjan Y Sardesai; David B Weiner; Mark L Bagarazzi
Journal:  Lancet       Date:  2015-09-17       Impact factor: 79.321

10.  High-resolution genomic profiling of human papillomavirus-associated vulval neoplasia.

Authors:  K J Purdie; C A Harwood; K Gibbon; T Chaplin; B D Young; J B Cazier; N Singh; I M Leigh; C M Proby
Journal:  Br J Cancer       Date:  2010-03-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.